Results from a network meta-analysis indicated superior efficacy for the combination of anlotinib and TQB2450.<h4>Conclusion</h4>Anlotinib combined with PD-1/PD-L1 inhibitors demonstrates significant efficacy in treating multiple tumor types. The gene discussed is PDCD1; the disease is neoplasm.